MA50352A - Anticorps multispécifiques - Google Patents

Anticorps multispécifiques

Info

Publication number
MA50352A
MA50352A MA050352A MA50352A MA50352A MA 50352 A MA50352 A MA 50352A MA 050352 A MA050352 A MA 050352A MA 50352 A MA50352 A MA 50352A MA 50352 A MA50352 A MA 50352A
Authority
MA
Morocco
Prior art keywords
multispecific antibodies
multispecific
antibodies
Prior art date
Application number
MA050352A
Other languages
English (en)
Inventor
Matthias Brock
Tea Gunde
Christian Hess
Sebastian Meyer
Alexandre Simonin
David Urech
Stefan Warmuth
Original Assignee
Numab Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17195779.8A external-priority patent/EP3470426A1/fr
Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG
Publication of MA50352A publication Critical patent/MA50352A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA050352A 2017-10-10 2018-10-09 Anticorps multispécifiques MA50352A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17195779.8A EP3470426A1 (fr) 2017-10-10 2017-10-10 Anticorps multi-spécifique
EP18150465 2018-01-05
EP18167093 2018-04-12
EP18180814 2018-06-29

Publications (1)

Publication Number Publication Date
MA50352A true MA50352A (fr) 2020-08-19

Family

ID=63799025

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050352A MA50352A (fr) 2017-10-10 2018-10-09 Anticorps multispécifiques

Country Status (17)

Country Link
US (1) US12202911B2 (fr)
EP (1) EP3694873A1 (fr)
JP (1) JP7442443B2 (fr)
KR (1) KR102907331B1 (fr)
CN (1) CN111194323B (fr)
AU (1) AU2018348429B2 (fr)
BR (1) BR112020006999A2 (fr)
CA (1) CA3075969A1 (fr)
CL (2) CL2020000937A1 (fr)
CO (1) CO2020003882A2 (fr)
IL (1) IL273576B1 (fr)
MA (1) MA50352A (fr)
MX (1) MX2020003562A (fr)
PE (1) PE20200849A1 (fr)
SG (1) SG11202002982YA (fr)
WO (1) WO2019072868A1 (fr)
ZA (1) ZA202001294B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7132232B2 (ja) 2017-02-24 2022-09-06 マクロジェニクス，インコーポレーテッド Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用
IL271127B2 (en) * 2017-06-05 2024-10-01 Numab Therapeutics AG Novel anti-hsa antibodies
US11578133B2 (en) * 2017-10-10 2023-02-14 Namab Therapeutics AG Antibodies targeting CD137 and methods of use thereof
CA3082297A1 (fr) * 2017-11-13 2019-05-16 Crescendo Biologics Limited Molecules se liant a cd137 et psma
TWI839395B (zh) * 2018-10-09 2024-04-21 瑞士商Ｎｕｍａｂ治療公司 靶向cd137的抗體及其使用方法
WO2021013142A1 (fr) * 2019-07-22 2021-01-28 江苏恒瑞医药股份有限公司 Anticorps anti-4-1bb, fragment de liaison à l'antigène de celui-ci et anticorps bispécifique
CN114555638B (zh) 2019-10-11 2023-08-22 南京维立志博生物科技有限公司 结合4-1bb的抗体及其用途
EP3816185A1 (fr) * 2019-11-04 2021-05-05 Numab Therapeutics AG Anticorps multi-spécifique contra pd-l1 et antigène associé à une tumeur
CN114929734A (zh) * 2020-01-09 2022-08-19 豪夫迈·罗氏有限公司 新型含有4-1bbl三聚体的抗原结合分子
CA3180665A1 (fr) 2020-05-19 2021-11-25 Boehringer Ingelheim International Gmbh Molecules de liaison pour le traitement du cancer
MX2022014768A (es) * 2020-05-29 2023-01-11 Numab Therapeutics AG Anticuerpo multiespecifico.
CN114195900B (zh) * 2020-09-17 2024-02-23 普米斯生物技术(珠海)有限公司 一种抗4-1bb/pd-l1双特异性抗体及其用途
EP3988568A1 (fr) 2020-10-21 2022-04-27 Numab Therapeutics AG Traitement combiné
WO2022136693A1 (fr) 2020-12-23 2022-06-30 Numab Therapeutics AG Domaines variables d'anticorps et anticorps ayant une immunogénicité réduite
IL310292A (en) 2021-07-22 2024-03-01 Univ Dundee Medicinal myotains
US20250382363A1 (en) 2022-05-06 2025-12-18 Numab Therapeutics AG Antibody Variable Domains And Antibodies Having Decreased Immunogenicity
EP4273162A1 (fr) 2022-05-06 2023-11-08 Numab Therapeutics AG Domaines variables d'anticorps et anticorps présentant une immunogénicité réduite
WO2024240690A2 (fr) 2023-05-19 2024-11-28 Numab Therapeutics AG Domaines variables d'anticorps et anticorps présentant une immunogénicité réduite
WO2025133391A1 (fr) 2023-12-22 2025-06-26 Numab Therapeutics AG Anticorps multispécifiques ayant une spécificité pour cd47 et pdl1

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
CA1247080A (fr) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Sequences d'acides amines ayant une activite antigenique
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1377306A1 (fr) 2001-03-09 2004-01-07 Dyax Corp. Groupes de liaison d'albumine serique
US20030157561A1 (en) * 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
DE60226641D1 (de) 2001-12-03 2008-06-26 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
US20040071705A1 (en) 2002-06-21 2004-04-15 Dyax Corporation Serum protein-associated target-specific ligands and identification method therefor
EP1600459A3 (fr) 2002-06-28 2005-12-07 Domantis Limited Ligand
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
AU2003259294A1 (en) 2002-07-30 2004-02-16 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2502413A1 (fr) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Analyse quantitative d'isoformes de proteines utilisant la spectrometrie de masse a temps de vol par desorption/ionisation laser assistee par matrice
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
BRPI0518761A2 (pt) 2004-12-02 2008-12-09 Domantis Ltd fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente
CA2612241C (fr) 2005-07-01 2018-11-06 Medarex, Inc. Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
PL3241842T3 (pl) 2007-06-26 2024-06-10 F-Star Therapeutics Limited Prezentacja środków wiążących
US8629246B2 (en) 2007-09-26 2014-01-14 Ucb Pharma S.A. Dual specificity antibody fusions
WO2010035012A1 (fr) 2008-09-26 2010-04-01 Ucb Pharma S.A. Produits biologiques
EP4209510B1 (fr) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
EP2454285A2 (fr) 2009-07-16 2012-05-23 Glaxo Group Limited Domaines variables uniques de liaison anti-albumine sérique améliorés
NO2504364T3 (fr) 2009-11-24 2018-01-06
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
SG10201912092VA (en) 2010-09-09 2020-02-27 Pfizer 4-1bb binding molecules
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
MA41044A (fr) * 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
SG11201704283PA (en) * 2014-11-26 2017-06-29 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
AU2016219772A1 (en) * 2015-02-22 2017-09-21 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD137
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
EA201890041A1 (ru) 2015-06-15 2018-07-31 Нумаб Инновейшн Аг Гетеродимерный полиспецифичный формат антител
WO2017102835A1 (fr) * 2015-12-14 2017-06-22 Complix Nv Molécule de liaison comprenant un polypeptide-alphacorps et un anticorps
MX2018008308A (es) * 2016-01-11 2019-05-15 Inhibrx Inc Proteinas de fusion de union a 41bb multivalentes y multiespecificas.
US11578133B2 (en) 2017-10-10 2023-02-14 Namab Therapeutics AG Antibodies targeting CD137 and methods of use thereof
CA3074802A1 (fr) 2017-10-10 2019-04-18 Numab Therapeutics AG Anticorps ciblant pdl1 et procedes d'utilisation associes

Also Published As

Publication number Publication date
CN111194323A (zh) 2020-05-22
KR102907331B1 (ko) 2025-12-31
US20230192897A1 (en) 2023-06-22
EP3694873A1 (fr) 2020-08-19
WO2019072868A1 (fr) 2019-04-18
US12202911B2 (en) 2025-01-21
ZA202001294B (en) 2024-08-28
CL2021000028A1 (es) 2021-05-28
IL273576B1 (en) 2026-02-01
JP2021501744A (ja) 2021-01-21
PE20200849A1 (es) 2020-08-20
KR20200063155A (ko) 2020-06-04
AU2018348429B2 (en) 2025-08-28
MX2020003562A (es) 2020-10-01
CO2020003882A2 (es) 2020-05-29
SG11202002982YA (en) 2020-04-29
BR112020006999A2 (pt) 2020-10-06
AU2018348429A1 (en) 2020-03-12
IL273576A (en) 2020-05-31
CN111194323B (zh) 2024-07-09
CL2020000937A1 (es) 2020-09-25
JP7442443B2 (ja) 2024-03-04
CA3075969A1 (fr) 2019-04-18

Similar Documents

Publication Publication Date Title
EP3498840A4 (fr) Anticorps anti-lag-3
MA49034A (fr) Anticorps anti-lag3
MA47694A (fr) Anticorps anti-tigit
MA47268A (fr) Anticorps anti-gpc3
EP3423089A4 (fr) Anticorps anti-tigit
FR25C1022I2 (fr) Anticorps anti-pd-1
EP3334757A4 (fr) Anticorps anti-tigit
EP3297671A4 (fr) Anticorps anti-ror1
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
EP3387442A4 (fr) Anticorps anti-cd73 humanisés
EP3507307A4 (fr) Anticorps bispécifiques
EP3503920A4 (fr) Anticorps anti-ctla4
MA53297A (fr) Anticorps anti-icos
EP3334824A4 (fr) Anticorps anti-pd-1
EP3684806A4 (fr) Nouveaux anticorps anti-cd3epsilon
MA47472A (fr) Anticorps
EP3492591A4 (fr) Anticorps anti-b7-h4
EP3526247A4 (fr) Anticorps anti-il1-rap
HUE059592T2 (hu) Anti-transztiretin antitestek
EP3399992A4 (fr) Anticorps autoréticulants
EP3383915A4 (fr) Anticorps anti-pd-1
EP3617231A4 (fr) Anticorps anti-gpc-1
EP3484919A4 (fr) Anticorps anti-bêta-amyloïde
MA51134A (fr) Anticorps anti-alpha-synucléine
EP3526251A4 (fr) Anticorps anti-p53